Featured Blog Posts (11)

Trial of T-Cells Genetically-Engineered to Express an Anti-CD19 Chimeric Antigen Receptor Show Promise as NewTtreatment Approach for B-cell Malignancies

According to new data, researchers have made important progress in the development of a promising new treatment approach for B-cell malignancies using genetically engineered T-cells.

B-cell malignancies, known to be aggressive and frequently resistant to standard therapeutic regimens, remain a challenge for clinicians and patients. One promising new approach to these cancers is the use of genetically engineered T-cells that express chimeric…


Added by Peter Hofland, PhD on December 10, 2011 at 10:30am — No Comments

New Finding Pinpoints a Critical Gene Involved in Melanoma Growth and Provides a Framework for Discovering Ways to Tackle Cancer Drug Resistance

The past year has brought to light both the promise and the frustration of developing new drugs to treat melanoma , the most deadly form of skin cancer. Early clinical tests of a candidate drug aimed at a crucial cancer-causing gene revealed impressive results in patients whose cancers resisted all currently available… Continue

Added by Peter Hofland, PhD on November 24, 2010 at 11:30am — No Comments

Personalized Cancer Therapy Requires New Strategies for Cancer Drug Development

Millions of cancer patients worldwide may soon be able to receive more effective, personalized treatments for their disease thanks to developments in the understanding of cancer biology, experts will say at the Cancer Biology for Clinicians Symposium organized by the European Society for Medical Oncology (ESMO) in Nice, France on 26-27 November.

To make the most of this coming transformation, governments, pharmaceutical companies and doctors urgently… Continue

Added by Peter Hofland, PhD on November 25, 2010 at 10:30am — No Comments

New Discovery Halts Breast Cancer Stem Cells – Suggesting A New Drug Therapy Target

Breast cancer stem cells (CSCs), the aggressive cells thought to be resistant to current anti-cancer therapies and which promote metastasis, are stimulated by estrogen via a pathway that mirrors normal stem cell development. Disrupting the pathway, researchers at Tufts University School of Medicineand the Sackler School of Graduate Biomedical Sciences at Tufts University, were… Continue

Added by Peter Hofland, PhD on November 26, 2010 at 6:30am — No Comments

New Therapy Provide Significant Survival Benefit In Second-line Metastatic Hormone-refractory Prostate Cancer (mHRPC)

Data from the Phase III TROPIC study, which was the basis for the June 2010 U.S. Food and Drug Administration (FDA) approval of the novel taxane cabazitaxel (Jevtana® ) was published in the October 2, 2010 print edition of The Lancet in an article titled “Prednisone plus cabazitaxel or mitoxantrone for metastatic…


Added by Peter Hofland, PhD on October 1, 2010 at 11:30am — No Comments

Cancer Tutorial: Introduction to Drug Resistance

Although the development of new drugs and new drug combinations has resulted in more effective treatment of cancer, a major factor limiting their usefulness is the presence of drug-resistant cancer cells that can exist prior to (intrinsic or de novo drug resistnace) or arise during cancer therapy (acquired drug resistance). Whether drug resistance is intrinsic or acquired, mechanisms conferring altered drug sensitivity may be categorized as invloving a pre-target event, a drug-target… Continue

Added by Roxanne Engel, PhD on January 6, 2010 at 11:41am — No Comments

Scientists Unveil Genetic Code for Skin and Lung Cancer

Research teams led by the Wellcome Trust Sanger Institute announced that they have sequenced the malignant melanoma and lung cancer cell genomes. Their data has been reported in back to back publications in this months issue of Nature. The studies reveal for the first time essentially all the mutations in malignant melanoma and lung cancer.

To map the cancer genomes, the researchers sequenced a… Continue

Added by Roxanne Engel, PhD on December 29, 2009 at 6:30pm — No Comments

Aspirin Reduces Colon Cancer Deaths

This article is a copy posted in my blog, "What's New, Doc?" at www.carbohydratescankill.com. From the title, it may seem irrelevant to diabetes mellitus. However, the risk of cancer is increased among the diabetic patients.

A study, “Aspirin Use and Survival After Diagnosis of Colorectal Cancer”, published in the August 12, 2009 issue of Journal of American Medical Association, cites taking Aspirin regularly by the… Continue

Added by Robert Su on November 20, 2009 at 10:30pm — No Comments

Bisplatinates, a New Class of Platinum-Based Anti-Tumor Drugs, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents

Seattle -based Cell Therapeutics, Inc, biopharmaceutical company committed to developing an integrated portfolio of oncology products, today announced that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell… Continue

Added by Peter Hofland, PhD on November 29, 2009 at 11:30pm — No Comments

'Explore the Mystery of Blood' Teaches High School Students About Blood and Career Opportunities in the Field of Hematology

The American Society of Hematology (ASH),the world’s largest professional society concerned with the causes and treatment of blood disorders, and Scholastic, the global children’s publishing, education, and media company, are launching 'Explore the Mystery of Blood,' a dynamic science curriculum designed to… Continue

Added by Peter Hofland, PhD on November 23, 2009 at 1:00pm — No Comments

National Comprehensive Cancer Network Updates Guidelines to Incorporate Approved New Treatment Options

Two recent FDA approvals have prompted the National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world's leading cancer centers dedicated to improving the quality and effectiveness of care provided to patients with cancer, to update the NCCN Clinical Practice Guidelines in Oncology™ for Non-Hodgkin's Lymphomas to include ofatumumab (Azerra™, GlaxoSmithKline) and romidepsin (Istodax®, Gloucester… Continue

Added by Peter Hofland, PhD on November 23, 2009 at 12:00pm — No Comments

Featured Monthly Archives




Register for free to view all the Onco'Zine - The International Oncology Network content:


Onco'Zine is present here

Bookmark / Share



© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+